ZP 4982Alternative Names: ZP4982
Latest Information Update: 14 Jun 2016
At a glance
- Originator Zealand Pharma
- Class Antihyperglycaemics; Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus